Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Robert J. Kreitman, Claire E. Dearden, Pier Luigi Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D le Coutre, Bjorn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Wyndham Wilson, Ira Pastan, Francis J. Giles
Institutions: National Institutes of Health, National Cancer Institute, Royal Marsden Hospital, Istituto di Ematologia di Bologna, Hospital Clínic de Barcelona, Medical University of Lodz, Charité - Universitätsmedizin Berlin, Haukeland University Hospital, Centre Hospitalier Universitaire de Caen Normandie, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, Hôpital Lyon Sud, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Acerta Pharma BV (Netherlands), Center for Cancer Research, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2983372623